And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma.

Abstract

Advances in the understanding of biology and therapy of melanoma have occurred at an astonishing pace over the past approximately 15 years, and successful melanoma therapy has led the way for similar advances in many other solid tumors that are continuing to improve outcomes for all patients with cancer. Although the 2018 Nobel Prize was awarded to two investigators who discovered that therapeutic targeting of immune checkpoints held the key to major patient benefits, there are many additional immunotherapeutic strategies that warrant further study and discussion at scientific and medical meetings. This article provides the newest information on three areas of immunotherapy that have been successfully applied to melanoma and continue to pave the way for new developments: cytokines, adoptive cell therapies (ADTs), and intratumoral injection of immunomodulatory agents.

• Authors: Isabella Claudia Glitza, Stephanie L Goff, Merrick Ross, Kim Margolin
• Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (Am Soc Clin Oncol Educ Book) Vol. 40 Pg. 1-12 (Mar 2020) ISSN: 1548-8756 [Electronic] United States
• PMID: 32243202 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Immunological
• Cytokines

Topics

• Antineoplastic Agents, Immunological (therapeutic use)
• Cell Transplantation
• Clinical Trials as Topic
• Cytokines (therapeutic use)
• Humans
• Immunotherapy (methods)
• Immunotherapy, Adoptive
• Melanoma (therapy)
• Survival Analysis
• Treatment Outcome